Search Results
223 Results Found for “disease characteristics”
Leading Alzheimer's disease experts share the therapeutic and research developments they believe had the greatest potential to transform diagnosis, treatment and prevention at the Alzheimer's Association International Conference (AAIC) 2026. The Alzheimer's Association International Conference (AAIC) 2026 showcased advances across the Alzheimer's ...
Dr Joost Smolders discusses the biology of broad rim lesions, their association with faster disability accumulation and how they could help inform future prognostication and treatment strategies in multiple sclerosis. Emerging biomarkers capable of identifying patients at risk of rapid ...
Explore the key characteristics of MOGAD and how best to recognize, differentiate, and diagnose the condition.
In this narrative review, we aim to introduce the reader to the history of calcitonin gene-related peptide (CGRP) discovery and its involvement in migraine pathophysiology. We will then look at drug development and clinical trials in migraine. We will additionally ...
Findings from AAN 2026 highlight a potential “survival paradox” associated with GLP-1 analogue use in older adults with diabetes At American Academy of Neurology 2026, Isaac Thorman (New York Medical College, Valhalla, NY, USA) presented new real-world data exploring the relationship between ...
The 19th European Headache Congress (EHC25) was held in Lisbon and brought together headache specialists, researchers and healthcare professionals from across Europe and beyond. Under the theme Transforming challenges into solutions, the congress focused on translating advances in headache science into meaningful improvements in clinical care. The meeting addressed key challenges in the prevention, diagnosis and treatment of headache and facial pain disorders, with an emphasis on bridging basic science, translational research and real-world clinical practice.
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...
In general, headaches can be classified into primary headaches (where no underlying disease is found) and secondary headaches (where a predefined condition is the cause of the headache). According to the International Classification of Headache Disorders, third edition (ICHD-3), primary ...
Nominated as a touchNEUROLOGY Future Leader 2025, and in collaboration with International Forum on Mood and Anxiety Disorders (IFMAD) 2025 rising star award, Dr Laure shares the key experiences, mentors and emerging treatment strategies that shape her evolving career. Her contributions to the Group for the Study of Resistant Depression (GSRD), combined with award-winning clinical work, mark her as one to watch in the field of psychiatry and psychotherapy.
Broadest approval to date in generalized myasthenia gravis The FDA approval of nipocalimab for generalized myasthenia gravis (gMG) introduces a targeted therapy within a validated class, offering the potential for durable disease control across the broadest patient population to date. ...
In this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% ...
Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ...
Diabetic striatopathy (DS) is a rare hyperglycaemic condition associated with one or both of the following criteria: (1) acute-onset chorea–ballism (random, flowing and nonsuppressible involuntary movements) and (2) striatal hyperdensity on computed tomography (CT) scan or T1-weighted magnetic resonance imaging (...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
